Metastatic Colorectal Cancer Therapeutics Market Size to Hit US$ 22.41 Billion by 2031 | Growth Plus Reports
Growth Plus Reports
Updated 6 min read
Growth Plus Reports
Newark, New Castle, USA, June 21, 2023 (GLOBE NEWSWIRE) -- According to the most recent analysis by Growth Plus Reports, the metastatic colorectal cancer therapeutics market was valued in 2022 at US$ 15.63 billion and is expected to register a revenue CAGR of 4.09% to hit US$ 22.41 billion by 2031.
The global market for metastatic colorectal cancer therapeutics was analyzed and is expected to rise significantly during the forecast period. The third most common kind of cancer, colorectal cancer (CRC), usually results from metastasis, which is the main cause of mortality. The peritoneum and the liver are frequent locations for distant metastases.
Metastatic Colorectal Cancer Therapeutics Market Scope
Report Attribute
Details
Market size Value in 2022
US$ 15.63 billion
Market Size Value in 2031
US$ 22.41 billion
Growth Rate
CAGR of 4.09% from 2023 to 2031
Base Year for Estimation
2022
Forecast Period
2023 to 2031
Historical Year
2021
Segments Covered
Treatment Regime, Therapy, End User, and Region
Regional Scope
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Competitive Landscape
Following is a list of the top market players operating in the global market for metastatic colorectal cancer therapeutics:
3M Company
Cardinal Health
Smith & Nephew plc
DermaRite Industries LLC
ConvaTec Group plc
B. Braun Melsungen AG
Key Takeaways:
Several environmental and genetic factors raise the likelihood of acquiring the condition driving the market revenue share.
The introduction of new front-line medicines is driving the demand for metastatic colorectal cancer therapeutics.
Several advancements and increasing biomedical R&D are creating a strong product pipeline.
Market Drivers and Restraints:
The driving factor for the metastatic colorectal cancer therapeutics market revenue is the rising number of patients acquiring the disease. Furthermore, novel research for introducing genetic treatments and other options for metastatic colorectal cancer therapy is contributing to the market revenue growth.
However, the high expense of target medicines and drug resistance are restraining market revenue growth.
Market Segmentation:
Segmentation By Treatment Regime
Based on the treatment regime, the global metastatic colorectal cancer therapeutics market is segmented into monotherapy and combination therapy. Due to its effectiveness in treating colorectal cancer in its early stages, the monotherapy segment accounts for the largest market revenue share. The therapy can be administered orally or intravenously, making it more convenient to use.
Segmentation By Therapy
Based on the therapy, the global metastatic colorectal cancer therapeutics market is segmented into chemotherapy, targeted therapy, immunotherapy, and others, being the most preferable and standard treatment option; the chemotherapy segment accounts for the largest revenue share.
Based on end-user, the global metastatic colorectal cancer therapeutics market is segmented into hospitals, cancer centers, ambulatory surgical centers, and others. The highest revenue share globally is accounted for by hospitals with the surgical suites, radiation therapy units, and oncology departments required for cancer diagnosis, treatment, and care.
Regional Growth Dynamics
Based on the region, the global metastatic colorectal cancer therapeutics market is segmented into North America, Asia Pacific, Latin America, Europe, and the Middle East & Africa. Due to the availability of a sophisticated healthcare system, a rising patient pool, and highly skilled healthcare professionals, North America accounts for the most significant revenue share in the global market.
Report Coverage
Growth Plus Reports studied the global market for metastatic colorectal cancer therapeutics in-depth and analyzed the basic market characteristics, significant investment areas, analytics of regional growth, revenue forecast, competitive market players, mergers, and acquisitions.
Table of Content
INTRODUCTION
Market Ecosystem
Timeline Under Consideration
Historical Years – 2021
Base Year – 2022
Forecast Years – 2023 to 2031
Currency Used in the Report
RESEARCH METHODOLOGY
Research Approach
Data Collection Methodology
Data Sources
Secondary Sources
Primary Sources
Market Estimation Approach
Bottom Up
Top Down
Market Forecasting Model
Limitations and Assumptions
PREMIUM INSIGHTS
Current Market Trends (COVID-19 Perspective)
Key Players & Competitive Positioning (2022)
Regulatory Landscape
Reimbursement Scenario
Epidemelogy and Patient Population Forecast to 2031
MARKET DYNAMICS
Drivers
Restraints
Opportunities
GLOBAL METASTATIC COLORECTAL CANCER THERAPEUTICS MARKET- ANALYSIS & FORECAST, BY TREATMENT REGIME
Monotherapy
Combination Therapy
GLOBAL METASTATIC COLORECTAL CANCER THERAPEUTICS MARKET- ANALYSIS & FORECAST, BY THERAPY
Chemotherapy
Targeted Therapy
Immunotherapy
Others
GLOBAL METASTATIC COLORECTAL CANCER THERAPEUTICS MARKET- ANALYSIS & FORECAST, BY END USER
COMT Inhibitors Marketby Drugs (Entacapone, Tolcapone), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Neurofibromatosis Marketby Type (NF1, NF2), Drug Class (Antihistamines, Antineoplastic Agents), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Synthetic Ovulation Stimulants Marketby Drug Class (Clomiphene Citrate (CC), Aromatase Inhibitors, GnRH Analogs), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) - Global Outlook and Forecast 2023-2031
Rasburicase Marketby Indication (Leukemia, Lymphoma, Solid Tumor Malignancies, Others), Patient Type (Adult, Pediatric) – Global Outlook & Forecast 2023-2031
Antipsoriatics Marketby Type (Plaque Psoriasis, Psoriatic Arthritis), Drug Type (TNF Inhibitors, Interleukins, Retinoids), Route of Administration (Oral, Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) -Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
